<DOC>
	<DOCNO>NCT01338675</DOCNO>
	<brief_summary>In study investigator plan use optimal busulfan dose pharmacokinetic study stem cell transplantation CGD patient .</brief_summary>
	<brief_title>Targeted Busulfan , Fludarabine Conditioning Regimen Hematopoietic Stem Cell Transplantation Chronic Granulomatous Disease ( CGD )</brief_title>
	<detailed_description>Chronic granulomatous disease one rare congenital immunodeficiency cure hematopoietic stem cell transplantation . Previous myeloablative condition regimen problem relate severe toxicity , non-myeloablative conditioning regimen risk graft failure . Recently , reduced-intensity myeloablative conditioning regimen busulfan fludarabine use usually leukemia patient . Busulfan highly toxic drug narrow therapeutic window . In study plan use optimal busulfan dose pharmacokinetic study stem cell transplantation CGD patient .</detailed_description>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients diagnose CGD . Patients need hematopoietic stem cell transplantation busulfan base condition regimen . Age : No limit . Performance status : ECOG 02 . Patients must free significant functional deficit major organ , follow eligibility criterion may modify individual case . Heart : shortening fraction &gt; 30 % ejection fraction &gt; 45 % . Liver : total bilirubin &lt; 2 × upper limit normal ; ALT &lt; 3 × upper limit normal . Kidney : creatinine &lt; 2 × normal creatinine clearance ( GFR ) &gt; 60 ml/min/1.73m2 . Patients must lack active viral infection active fungal infection . Appropriate donor available . Patients ( one parent patient age &lt; 20 ) sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Chronic granulomatous disease</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
</DOC>